Please assess the completion status of the following clinical trial:

Trial Title: GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed the full 6 month treatment period with study drug in the previous Genelabs' clinical study GL02-01.~* Concomitant treatment with prednisone (or equivalent) at a dose of ≥ 5mg/day.~* Patient has read and signed an Informed Consent Form. If the patient is not fluent in English, the Informed Consent must be signed in her native language.~Exclusion Criteria:~* Patient has had a serious study drug related adverse reaction at any time during the previous GL02-01 study.~* Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease).~MEDICATIONS PROHIBITED AT ANY TIME DURING THE STUDY~* Calcitonin~* Bisphosphonates~* Fluoride at pharmacologic dose~* Strontium at pharmacologic dose~* Estrogenic steroids (except oral contraceptives)~* Selective Estrogen Receptor Modulator (raloxifene)~* Parathyroid hormone~* Any androgens, including prescription or nutritional supplement DHEA, other than study drug~* Additional Calcium supplements other than those prescribed as part of this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).